PubRank

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Clinical Trial ID NCT01087294

PubWeight™ 26.70‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01087294

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010 3.57
2 Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013 3.45
3 Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014 2.84
4 Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013 1.91
5 Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol 2013 1.64
6 Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol 2014 1.61
7 Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells. Front Immunol 2013 0.98
8 CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL). Ther Adv Hematol 2015 0.95
9 Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep 2014 0.89
10 Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. Leukemia 2014 0.86
11 Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood 2016 0.86
12 Clinical development of gene therapy: results and lessons from recent successes. Mol Ther Methods Clin Dev 2016 0.85
13 Immunotherapy for pediatric leukemia. Front Oncol 2013 0.84
14 Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol 2012 0.84
15 Genetically engineered T cells for the treatment of cancer. J Intern Med 2013 0.83
16 Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances. Ther Adv Hematol 2015 0.82
17 Challenges and opportunities of allogeneic donor-derived CAR T cells. Curr Opin Hematol 2015 0.79
18 Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors. World J Stem Cells 2015 0.78
19 Using gene therapy to manipulate the immune system in the fight against B-cell leukemias. Expert Opin Biol Ther 2015 0.77
20 Management of patients with non-Hodgkin's lymphoma: focus on adoptive T-cell therapy. Immunotargets Ther 2015 0.75
21 Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. Pediatr Blood Cancer 2015 0.75
Next 100